Business Wire

Allente Among World’s First Operators to Integrate Google Common Broadcast Stack, supported by KAON and 3SS

24.8.2021 10:00:00 EEST | Business Wire | Press release

Share

3 Screen Solutions (3SS) and KAONMEDIA (KOSDAQ: KAON MEDIA) jointly announce the completion of their hybrid STB (set-top box) integration for Nordic pay-TV giant Allente.

This accomplishment is a milestone achievement which makes Allente one of the world’s first operators to complete Google Common Broadcast Stack integration for an Android TV Operator Tier STB. The project was completed in just six months thanks to close collaboration between Allente, KAONMEDIA, NAGRA, Broadcom, 3SS and Google.

The partnership of 3SS and KAON to deliver Allente’s new service was announced in October 2020. Powerful hybrid KAON BCM72180 PVR STBs will be available to Allente’s over 1 million subscribers, with NAGRA Media CAS, Broadcom 72180 SoC and based on 3SS UX technology, in Q3 2021.

Google created its standardized Common Broadcast Stack (CBS) to accelerate the reach of Android TV OS worldwide. Announced in October 2020, CBS will help more TV viewers to get the next-generation app-rich services they crave. A Broadcast Stack is the software designed for STBs and other TV devices that enables playing and recording of digital TV broadcast signals. Among the positive outcomes of adopting CBS are easier and faster integration for hybrid Android TV OS devices, accelerated time-to-market, simplified upgrades and reduced overall TCO (total cost of ownership). Additionally, with CBS being collectively optimized through Google’s wide-ranging tech partner network, service providers and their subscribers can be even more confident of a superior, next-level Android TV OS viewing experience.

“We congratulate Allente for becoming one of the first operators in the world to leverage the Common Broadcast Stack, and in working closely with world-class technology partners, elevating the digital entertainment user experience for consumers,” commented Matthias Puschmann, Strategic Android TV Partner Development Manager at Google.

The Nordic region’s pre-eminent pay-TV provider, Allente is further building upon its first successful 3SS-enabled project. OnePlace is the satellite and OTT service which Canal Digital launched in February 2018. In 2019 the service was named “Best TV User Experience” in the prestigious CSI Awards. Allente was later formed from the merger of Viasat Consumer and Canal Digital in May 2020, and offers TV via satellite, streaming and other services including IPTV and fibre broadband via open networks to customers in Norway, Sweden, Denmark and Finland.

Allente’s new hybrid KAON BCM72180 PVR STB will give subscribers a range of benefits from high performance to a proven next-gen 3SS-engineered customer experience.

Jon Espen Nergård, Allente CTO, said, “Completion of our STB integration so rapidly is a clear testament to the technology, engineering skill and dedication to customer satisfaction from our partners KAON and 3SS, and indeed those of our wider partnership of collaborators which includes NAGRA, Broadcom and of course Google.”

KAON STB middleware is fully integrated with the Android TV software stack to enable new pre-certified Android TV capabilities such as Custom Over-The-Air Update, among others, further accelerating the introduction of new appealing features.

“We are extremely proud to be the first OEM to complete STB integration on a Broadcom SoC with NAGRA CAS seamlessly integrated with UX delivered by 3SS,” commented Tom Buhl, KAON Media Executive Vice President. “The rapid pace of integration with our highly esteemed partners could hardly be more powerful evidence of the many benefits made possible by the Google Common Broadcast Stack,” he added.

“Our ongoing partnership of trust with Allente is a source of tremendous pride for the entire team at 3SS,” commented Kai-Christian Borchers, Managing Director of 3SS. “In becoming one of the world’s first service providers to embrace Google’s Common Broadcast Stack, Allente is blazing a new trail in innovation and customer focus; we eagerly anticipate helping Allente to deliver leading-edge viewing to consumers in the Nordic region,”

SAFe means speedy integration

This project was accelerated thanks to modern principles of agile development, which were first introduced to Canal Digital by 3SS. At the heart is “SAFe” (Scaled Agile Framework), the practical experience-based software development framework which accelerates and optimizes system deployments.

With SAFe, all stakeholders in a project, both in-house and partners, know the status of objectives and exactly where they are in the progress of a granular roadmap of deliverables. SAFe delivers accelerated, streamlined innovation, better productivity, effective planning and superior products.

Google, Google Play and Android TV are trademarks of Google LLC.

About Allente
Allente is a leading Nordic TV operator, providing top quality TV and broadband services to over 1 million customers in Norway, Sweden, Denmark and Finland. The company was established in May 2020 by a merger between Canal Digital and Viasat Consumer. In 2020, the two companies had combined net sales of SEK 7 billion. Allente is owned 50/50 by Telenor Group and NENT Group. www.allente.se

About KAON
KAON is a technology leader in pay-TV and broadband solutions. We ensure the connected home technology which enables consumers to simply change the way they experience entertainment and information within the home with the full line-up of innovative platforms and service solutions to give users easy access to multi-screen experiences anywhere, at any time. KAONMEDIA is well recognized by Tier 1 Operators in more than 90 countries. Headquartered in South Korea, KAONMEDIA has global presence in over 24 countries including Germany, Norway, France, Spain, Netherlands, Australia, USA, Brazil, Mexico, Colombia, Japan, and others. www.kaonmedia.com

About 3 Screen Solutions (3SS)
Since 2009, 3SS has been delivering world-class software solutions to service providers and technology innovators to bring video to any screen. 3SS is an acknowledged leader in system integration, app development, UI/UX design innovation and solution architecture. 3SS designs and engineers front end and back end platforms for major operators and broadcasters worldwide to make customer experiences easier and more personal. 3SS’ customers include major satellite, cable, IPTV, OTT and mobile TV operators, including Swisscom, Com Hem (Tele2), Allente, Proximus, TCC Uruguay, FreeCast (SelectTV), Altibox, ORS (simpliTV), Yes (STINGTV), Vodafone Kabel Deutschland, Stofa, Liberty Global (UPC, Unitymedia), SES, Eutelsat, and O2/Telefonica. Broadcast customers include ProSiebenSat.1, Joyn (ProSiebenSat.1/Discovery), SUPER RTL (TOGGO), n-tv, Blockbuster and Viacom, among others. 3ss.tv, 3ready.tv

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For KAON
Andrew Shin
+82 31 724 8609
andrew.shin@kaonmedia.com

For 3SS
Cynthia Ritchie
+44 20 3514 2525
cynthia@whitetigercommunications.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye